| 2024-01-04 | -40.5% | legal | SEC EDGAR | OPK 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-01-24 | -28.2% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2024-03-28 | +22.6% | legal | SEC EDGAR | OPK 8-K: 1.01, 7.01 (SEC Filing) |
| 2023-05-03 | +16.4% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2023-03-08 | +15.8% | legal | SEC EDGAR | OPK 8-K: 1.01 and (SEC Filing) |
| 2022-05-09 | +14.8% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2022-05-09 | +14.8% | M&A | OPKO Health, Inc. | OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases - OPKO Health, Inc. |
| 2023-08-03 | +13.8% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2022-11-08 | -13.3% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2021-07-29 | -11.5% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2021-05-07 | -11.2% | legal | SEC EDGAR | OPK 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-07-31 | -9.2% | earnings | Seeking Alpha | OPKO Health GAAP EPS of -$0.19 misses by $0.08, revenue of $156.8M misses by $8.9M |
| 2025-07-31 | -9.2% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-07-31 | -9.2% | legal | OPKO Health, Inc. | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc. |
| 2021-07-12 | -8.7% | legal | SEC EDGAR | OPK 8-K: 1.01 (SEC Filing) |
| 2024-01-05 | +8.3% | legal | SEC EDGAR | OPK 8-K: 8.01 and (SEC Filing) |
| 2021-09-03 | -7.8% | legal | SEC EDGAR | OPK 8-K: 1.01 and (SEC Filing) |
| 2024-11-08 | +7.7% | earnings | Seeking Alpha | OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript |
| 2024-07-17 | +7.7% | legal | SEC EDGAR | OPK 8-K: 1.01, 2.03, 7.01 (SEC Filing) |
| 2024-07-17 | +7.7% | earnings | OPKO Health, Inc. | OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments - OPKO Health, Inc. |
| 2025-02-28 | +7.6% | earnings | Seeking Alpha | OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript |
| 2023-06-30 | +7.4% | legal | SEC EDGAR | OPK 8-K: 1.01 (SEC Filing) |
| 2022-08-04 | -6.3% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2024-09-16 | +5.5% | legal | SEC EDGAR | OPK 8-K: 1.02, 2.01, 7.01 (SEC Filing) |
| 2024-05-07 | -5.4% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2024-05-07 | -5.4% | news | Stock Titan | OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results - Stock Titan |
| 2025-09-19 | -5.3% | news | simplywall.st | OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up - simplywall.st |
| 2022-07-15 | -5.2% | legal | SEC EDGAR | OPK 8-K: 1.01, 5.07 (SEC Filing) |
| 2022-04-15 | -5.1% | news | OPKO Health, Inc. | April 20, 2022 - 8-K: Current report filing - OPKO Health, Inc. |
| 2024-08-07 | +5.1% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2023-05-19 | -5.0% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2025-02-27 | +4.9% | earnings | Seeking Alpha | OPKO stock climbs 4% on better-than-expected Q4 report |
| 2025-02-27 | +4.9% | earnings | Seeking Alpha | OPKO Health GAAP EPS of $0.01 beats by $0.11, revenue of $183.6M beats by $28.18M |
| 2025-02-27 | +4.9% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-02-27 | +4.9% | earnings | Stock Titan | OPKO Health Swings to Profit: Can This Healthcare Turnaround Story Maintain Momentum? - Stock Titan |
| 2025-02-27 | +4.9% | news | GlobeNewswire | OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results - GlobeNewswire |
| 2023-03-01 | +4.9% | news | Seeking Alpha | Few Options Left For OPKO Health, Inc. To Heal (NASDAQ:OPK) - Seeking Alpha |
| 2025-08-11 | +4.7% | news | Yahoo Finance | Phillip Frost Buys Handful Of Shares In OPKO Health - Yahoo Finance |
| 2021-10-28 | +4.7% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-07-30 | -4.7% | earnings | Seeking Alpha | OPKO Health Q2 2025 Earnings Preview |
| 2025-10-31 | -4.6% | M&A | Yahoo Finance | Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)? - Yahoo Finance |
| 2022-05-04 | -4.6% | legal | SEC EDGAR | OPK 8-K: 1.01, 8.01 (SEC Filing) |
| 2021-04-28 | -4.4% | legal | SEC EDGAR | OPK 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-29 | +4.3% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2025-04-30 | -4.3% | earnings | Seeking Alpha | Opko health outlines $675M-$685M revenue guidance for 2025 amid strategic initiatives |
| 2025-04-30 | -4.3% | earnings | Seeking Alpha | OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript |
| 2025-04-30 | -4.3% | earnings | Seeking Alpha | OPKO Health GAAP EPS of -$0.10 misses by $0.03, revenue of $149.9M misses by $14.36M |
| 2025-04-30 | -4.3% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-04-30 | -4.3% | news | OPKO Health, Inc. | OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc. |
| 2026-01-14 | -4.3% | news | Yahoo Finance | Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns - Yahoo Finance |
| 2025-10-30 | -4.1% | earnings | Seeking Alpha | OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript |
| 2025-10-30 | -4.1% | expansion | Yahoo Finance | Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Yahoo Finance |
| 2022-05-13 | +4.1% | legal | SEC EDGAR | OPK 8-K: 1.01, 3.02, 5.02 (SEC Filing) |
| 2025-04-07 | -4.1% | news | Intellectia AI | OPK Forecast — Price Prediction for 2026. Should I Buy OPK? - Intellectia AI |
| 2026-02-25 | +4.1% | earnings | Seeking Alpha | OPKO Health Q4 2025 Earnings Preview |
| 2022-04-20 | -4.0% | legal | SEC EDGAR | OPK 8-K: 8.01 (SEC Filing) |
| 2025-05-28 | +4.0% | news | Seeking Alpha | SA Asks: What are the best oncology stocks right now? |
| 2026-03-27 | -3.9% | news | GlobeNewswire | Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates |
| 2026-03-27 | -3.9% | analyst | Simply Wall St. | How The OPKO Health (OPK) Story Is Shifting With Mixed Analyst Signals |
| 2026-03-27 | -3.9% | analyst | Yahoo Finance | How The OPKO Health (OPK) Story Is Shifting With Mixed Analyst Signals - Yahoo Finance |
| 2026-02-27 | +3.8% | earnings | Seeking Alpha | OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript |
| 2026-02-27 | +3.8% | earnings | Yahoo Finance | OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts - Yahoo Finance |
| 2025-09-23 | +3.6% | news | Yahoo Finance | 44% of OPKO Health, Inc. (NASDAQ:OPK) is owned by insiders, and they've been buying recently - Yahoo Finance |
| 2022-02-24 | +3.6% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-11-18 | +3.6% | executive | Investing.com | Opko Health CEO Phillip Frost buys $737,747 in OPK stock - Investing.com |
| 2025-04-04 | +3.5% | news | Seeking Alpha | OPKO Health authorizes $100 million increase to share buyback program |
| 2025-11-04 | -3.4% | executive | simplywall.st | Insider Buying: OPKO Health Chairman & CEO Bought US$213k Of Shares - simplywall.st |
| 2026-02-28 | +3.3% | earnings | simplywall.st | OPKO Health (OPK) Loss Worsens To US$0.30 TTM EPS Challenging Turnaround Narratives - simplywall.st |
| 2025-03-28 | -3.2% | legal | SEC EDGAR | OPK 8-K: 1.01 and 3.02 (SEC Filing) |
| 2026-02-06 | -3.2% | expansion | Yahoo Finance | Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Yahoo Finance |
| 2025-12-09 | +3.2% | news | Yahoo Finance | Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - Yahoo Finance |
| 2025-11-03 | +3.2% | analyst | Yahoo Finance | Some OPKO Health, Inc. (NASDAQ:OPK) Analysts Just Made A Major Cut To Next Year's Estimates - Yahoo Finance |
| 2025-11-03 | +3.2% | earnings | Sahm | A Look at OPKO Health (OPK) Valuation Following Regeneron Deal, Oncology Sale, and Earnings Surprise - Sahm |
| 2026-04-08 | -3.1% | news | MT Newswires | OPKO Health's ModeX Therapeutics Doses First Participants in Phase 1 Trial of MDX2301 for Prevention of COVID-19 |
| 2026-04-08 | -3.1% | news | GlobeNewswire | OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 |
| 2026-04-08 | -3.1% | news | Stock Titan | A new COVID antibody enters human testing for high-risk adults - Stock Titan |
| 2025-12-23 | -3.1% | analyst | DirectorsTalk Interviews | Opko Health, Inc. (OPK) Stock Analysis: A Look At Growth Potential And Analyst Ratings - DirectorsTalk Interviews |
| 2026-03-03 | -3.0% | news | DirectorsTalk Interviews | Opko Health, Inc. (OPK) Stock Analysis: Exploring a 174% Potential Upside Amidst Challenging Fundamentals - DirectorsTalk Interviews |
| 2026-04-03 | +3.0% | news | Cổng thông tin điện tử Tỉnh Sơn La | OPK Stock Analysis: OPKO Health Inc. 1.14 healthcare stock gains 0.88 pct today - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-06-11 | -3.0% | news | Seeking Alpha | OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy |
| 2025-06-11 | -3.0% | news | Seeking Alpha | OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha |
| 2025-03-11 | -3.0% | news | Seeking Alpha | Labcorp to buy certain assets of OPKO unit BioReference Health |
| 2025-03-11 | -3.0% | legal | SEC EDGAR | OPK 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-07-29 | -2.9% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2025-04-29 | -2.8% | earnings | Seeking Alpha | OPKO Health Q1 2025 Earnings Preview |
| 2026-02-26 | +2.7% | earnings | Seeking Alpha | OPKO Health Non-GAAP EPS of -$0.04 beats by $0.03, revenue of $148.5M beats by $8.74M |
| 2026-02-26 | +2.7% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +2.7% | news | OPKO Health, Inc. | OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc. |
| 2026-02-26 | +2.7% | earnings | Yahoo Finance | Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics - Yahoo Finance |
| 2026-02-26 | +2.7% | earnings | Yahoo Finance | OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-02-26 | +2.7% | earnings | Stock Titan | OPKO Health inks $1B-plus Regeneron antibody pact in Q4 update - Stock Titan |
| 2026-02-26 | +2.7% | earnings | Investing.com Canada | OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ... By GuruFocus - Investing.com Canada |
| 2026-02-26 | +2.7% | earnings | marketscreener.com | OPKO Health: Q4 Earnings Snapshot - marketscreener.com |
| 2025-03-20 | -2.7% | executive | Yahoo Finance | Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance |
| 2025-10-22 | +2.6% | earnings | Quiver Quantitative | OPKO Health, Inc. to Announce Q3 2025 Financial Results and Business Update on October 29, 2025 - Quiver Quantitative |
| 2025-10-29 | +2.4% | earnings | Seeking Alpha | OPKO Health GAAP EPS of $0.03 beats by $0.07, revenue of $151.7M misses by $14.04M |
| 2025-10-29 | +2.4% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-10-29 | +2.4% | news | Yahoo Finance | OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results - Yahoo Finance |
| 2025-10-29 | +2.4% | M&A | Stock Titan | OPKO Health (NASDAQ: OPK) in Regeneron deal: $7M upfront, up to $200M per molecule - Stock Titan |
| 2026-03-26 | -2.4% | news | Seeking Alpha | OPKO Health: The Waiting Game Continues |
| 2026-03-26 | -2.4% | news | Seeking Alpha | OPKO Health: The Waiting Game Continues (NASDAQ:OPK) - Seeking Alpha |
| 2025-03-14 | +2.4% | news | Yahoo Finance | Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Yahoo Finance |
| 2026-03-19 | -2.3% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2026-03-19 | -2.3% | executive | Stock Titan | OPKO Health (OPK) appoints former CFO Subbarao Uppaluri to board - Stock Titan |
| 2026-03-19 | -2.3% | executive | Investing.com | OPKO Health appoints Subbarao V. Uppaluri to board of directors - Investing.com |
| 2026-03-19 | -2.3% | news | TipRanks | Opko Health Adds Independent Director to Strengthen Governance - TipRanks |
| 2021-06-23 | -2.3% | legal | SEC EDGAR | OPK 8-K: 1.01 (SEC Filing) |
| 2022-08-12 | +2.3% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for OPKO Health (OPK) - Zacks Investment Research |
| 2025-08-17 | +2.2% | news | Yahoo Finance | OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics - Yahoo Finance |
| 2024-11-07 | +2.2% | earnings | Seeking Alpha | OPKO Health GAAP EPS of $0.03 beats by $0.12, revenue of $173.6M misses by $7.93M |
| 2024-11-07 | +2.2% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2024-11-07 | +2.2% | news | OPKO Health, Inc. | OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results - OPKO Health, Inc. |
| 2022-08-16 | -2.2% | legal | SEC EDGAR | OPK 8-K: 5.02 and (SEC Filing) |
| 2025-10-07 | -2.1% | news | DirectorsTalk Interviews | Opko Health, Inc. (OPK) Stock Analysis: A High-Stakes Bet With 129% Potential Upside - DirectorsTalk Interviews |
| 2026-04-06 | +2.1% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is OPKO Health (OPK) Stock Rebounding | Price at $1.16, Up 1.93% - Market Analysis - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-06 | +2.1% | news | Xã Châu Thành | Is OPKO Health (OPK) Stock Rebounding | Price at $1.16, Up 1.93% - Stock Screening - Xã Châu Thành |
| 2023-01-03 | +2.1% | legal | SEC EDGAR | OPK 8-K: 8.01 (SEC Filing) |
| 2026-01-27 | -1.9% | news | Seeking Alpha | OPKO Health: Deeply Mispriced Ahead Of Major Catalysts |
| 2026-01-27 | -1.9% | news | Seeking Alpha | OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha |
| 2021-06-21 | +1.8% | legal | SEC EDGAR | OPK 8-K: 1.01 and (SEC Filing) |
| 2022-04-27 | -1.7% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2025-02-12 | +1.7% | news | Yahoo Finance | Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy? - Yahoo Finance |
| 2024-10-17 | -1.7% | news | Yahoo Finance | With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future - Yahoo Finance |
| 2026-01-15 | -1.7% | news | Seeking Alpha | OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-15 | -1.7% | news | simplywall.st | A Look At OPKO Health (OPK) Valuation As Shares Trade Around US$1.30 - simplywall.st |
| 2025-10-28 | -1.7% | earnings | Seeking Alpha | OPKO Health Q3 Earnings Preview |
| 2025-10-28 | -1.7% | news | Yahoo Finance | OPKO Health (NASDAQ:OPK investor five-year losses grow to 58% as the stock sheds US$64m this past week - Yahoo Finance |
| 2022-03-25 | +1.7% | news | Yahoo Finance | OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance |
| 2024-01-24 | -1.7% | legal | SEC EDGAR | OPK 8-K: 8.01 (SEC Filing) |
| 2025-12-16 | -1.6% | news | simplywall.st | Does OPKO Health’s Recent Rebound Signal a Mispriced Opportunity in 2025? - simplywall.st |
| 2022-09-01 | -1.5% | analyst | TradingView | OPK Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-04-01 | -1.5% | legal | SEC EDGAR | OPK 8-K: 1.01 and 3.02 (SEC Filing) |
| 2025-09-11 | -1.5% | news | Yahoo Finance | Here's Why You Should Retain OPKO Health Stock in Your Portfolio - Yahoo Finance |
| 2025-05-01 | -1.5% | news | simplywall.st | OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt - simplywall.st |
| 2026-02-17 | -1.5% | expansion | Yahoo Finance | Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Yahoo Finance |
| 2026-03-29 | -1.5% | news | AD HOC NEWS | OPKO Health Inc Stock: Business Model, Growth Drivers, and Key Investor Considerations in Diagnostic - AD HOC NEWS |
| 2025-11-25 | +1.4% | news | DirectorsTalk Interviews | Opko Health, Inc. (OPK) Stock Analysis: Unpacking a 173.72% Potential Upside Amid Challenging Financials - DirectorsTalk Interviews |
| 2024-02-09 | +1.4% | legal | SEC EDGAR | OPK 8-K: 5.02 (SEC Filing) |
| 2023-12-21 | +1.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-02-10 | -1.4% | legal | SEC EDGAR | OPK 8-K: 1.01, 2.03and3.02 (SEC Filing) |
| 2025-11-20 | +1.3% | executive | Yahoo Finance | The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade - Yahoo Finance |
| 2025-11-20 | +1.3% | executive | simplywall.st | Does CEO Frost’s Share Purchase Offset Concerns About OPKO Health’s (OPK) Sales Outlook? - simplywall.st |
| 2023-11-06 | -1.3% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2026-04-14 | -1.2% | news | Insider Monkey | OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment |
| 2026-04-14 | -1.2% | news | Yahoo Finance | OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment - Yahoo Finance |
| 2025-09-15 | -1.1% | legal | SEC EDGAR | OPK 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-10-01 | -1.1% | news | Yahoo Finance | OPKO Health, Inc. (OPK)’s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1 - Yahoo Finance |
| 2025-10-15 | -1.1% | news | Seeking Alpha | OPKO Health: The Lab Sale Brings Focus, But Execution Still Key |
| 2025-10-15 | -1.1% | news | Seeking Alpha | OPKO Health: The Lab Sale Brings Focus, But Execution Still Key (NASDAQ:OPK) - Seeking Alpha |
| 2026-02-18 | -1.1% | M&A | Yahoo Finance | Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - Yahoo Finance |
| 2024-02-27 | -1.1% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2025-02-13 | -1.1% | earnings | Stock Titan | OPKO Health Sets Critical Q4 Earnings Date: What The Numbers Will Reveal - Stock Titan |
| 2026-03-20 | -1.0% | earnings | Yahoo Finance | Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy - Yahoo Finance |
| 2026-03-20 | -1.0% | news | Stock Titan | OPKO Health (NASDAQ: OPK) director granted 50,000 options at $1.17 - Stock Titan |
| 2026-03-20 | -1.0% | news | Stock Titan | OPKO Health (NASDAQ: OPK) director reports initial common stock holdings - Stock Titan |
| 2026-03-20 | -1.0% | news | Stock Titan | Opko Health (OPK) director adds 10,000 shares in open-market buy - Stock Titan |
| 2025-11-11 | -1.0% | legal | DirectorsTalk Interviews | Opko Health, Inc. (OPK) Investor Outlook: Exploring a 167% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews |
| 2025-04-12 | -1.0% | news | Seeking Alpha | Insider trades: Nike, Kroger, GameStop among notable names this week |
| 2021-05-21 | +1.0% | legal | SEC EDGAR | OPK 8-K: 1.02, 3.02and8.01 (SEC Filing) |
| 2025-02-26 | +0.9% | earnings | Seeking Alpha | OPKO Health Q4 Earnings Preview |
| 2026-04-20 | -0.8% | news | Cổng thông tin điện tử Tỉnh Sơn La | OPKO Health (OPK) Stock: Market Opportunity? (-2.42%) 2026-04-20 - Viral Trade Signals - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-02-04 | -0.7% | news | Stock Titan | Daily oral PTH tablet targets relief from hypoparathyroidism injections - Stock Titan |
| 2026-01-08 | -0.7% | news | simplywall.st | OPKO Health, Inc. (NASDAQ:OPK) insiders have recently purchased stock and their bets paid off last week as company hit US$1.0b market cap - simplywall.st |
| 2025-02-01 | -0.6% | news | Seeking Alpha | Insider trades: Verizon, Goldman Sachs among notable names this week |
| 2025-08-01 | -0.6% | earnings | Seeking Alpha | OPKO Health outlines $640M–$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push |
| 2025-08-01 | -0.6% | earnings | Seeking Alpha | OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript |
| 2026-04-22 | -0.6% | news | MT Newswires | OPKO Health's ModeX Therapeutics Begins Trial of MDX2003 for B-Cell Lymphoma |
| 2026-04-22 | -0.6% | news | GlobeNewswire | OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas |
| 2026-04-22 | -0.6% | earnings | MarketBeat | OPKO Health (OPK) to Release Earnings on Wednesday - MarketBeat |
| 2026-04-22 | -0.6% | news | Stock Titan | A four-target antibody enters human testing in B-cell lymphoma - Stock Titan |
| 2024-01-09 | +0.6% | legal | SEC EDGAR | OPK 8-K: 1.01, 1.02, 2.03, 3.02 (SEC Filing) |
| 2022-01-18 | +0.6% | legal | SEC EDGAR | OPK 8-K: 1.01 and (SEC Filing) |
| 2022-01-18 | +0.6% | M&A | OPKO Health, Inc. | Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform - OPKO Health, Inc. |
| 2025-07-23 | +0.6% | news | Yahoo Finance | OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) - Yahoo Finance |
| 2026-03-17 | -0.5% | news | DirectorsTalk Interviews | Opko Health, Inc. (OPK) Stock Analysis: A Glimpse Into Potential 185% Upside - DirectorsTalk Interviews |
| 2023-02-23 | +0.5% | legal | SEC EDGAR | OPK 8-K: 2.02 and (SEC Filing) |
| 2026-04-21 | +0.5% | news | GlobeNewswire | OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 |
| 2026-04-21 | +0.5% | earnings | Stock Titan | OPKO to give 2026 guidance and business update after April 28 results - Stock Titan |
| 2026-04-23 | -0.4% | analyst | Simply Wall St. | How The OPKO Health (OPK) Narrative Is Shifting After Mixed Results And A Lower Price Target |
| 2026-04-23 | -0.4% | news | Zacks | Here's Why You Should Hold OPK Stock in Your Portfolio for Now |
| 2026-04-23 | -0.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | OPK (OPKO Health) beats Q4 2025 EPS expectations but shares drop 2.02% amid 14.9% year-over-year revenue decline. - Viral Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-12-10 | +0.2% | news | Yahoo Finance | Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? - Yahoo Finance |
| 2025-11-24 | -0.2% | news | Trefis | With OPKO Health Stock Sliding, Have You Assessed The Risk? - Trefis |
| 2026-04-11 | -0.1% | earnings | MarketBeat | OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of "Hold" by Analysts - MarketBeat |
| 2026-04-27 | — | news | MSN | Here's why you should hold OPK stock in your portfolio for now - MSN |
| 2026-04-24 | — | news | MSN | Here's why you should hold OPK stock in your portfolio for now - MSN |